Format

Send to

Choose Destination
Am J Hematol. 2015 Jul;90(7):598-601. doi: 10.1002/ajh.24011.

Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.

Author information

1
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
2
Department of Pathology, Weill Medical College of Cornell University, New York, New York.
3
GlaxoSmithKline, Research Triangle Park, North Carolina.
4
GlaxoSmithKline, Stockley Park, United Kingdom.
5
GlaxoSmithKline, Collegeville, Pennsylvania.

Abstract

Thrombopoietin receptor agonists, which raise platelet counts in patients with chronic immune thrombocytopenia, may be associated with increases in bone marrow (BM) reticulin. Patients with chronic immune thrombocytopenia participating in the Eltrombopag Extended Dosing (EXTEND) study underwent BM biopsies to identify clinically relevant BM fibrosis-related increases. Specimens were centrally reviewed by 2 hematopathologists. Two hundred thirty-two biopsy specimens were collected from 117 patients treated for ≤5.5 years. Moderate to marked reticulin fibrosis was found in 2 patients. After withdrawing from the study, the biopsy of 1 patient reverted to normal. There were no other pathologic changes identified among on-treatment specimens, and no pattern of abnormal reticulin deposition associated with eltrombopag treatment was evident.

PMID:
25801698
DOI:
10.1002/ajh.24011
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center